

Dear Editor,

Thank you very much for your kind attention and the reviewers' evaluation. We have revised our manuscript according to the reviewer's comments. The table below presents all comments and our point-by-point replies. All the changes in the manuscript are highlighted in yellow.

Reviewer	Comment	Reply
	Page 6, line 88: Please update the reference n.6 with Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020 Jul;19(7):102554. doi: 10.1016/j.autrev.2020.102554.	Thanks for your kind comment. We updated the reference n.6 based on your recommendation.
	Page 7, line 92: Please add the reference related to the use of IVIg in COVID-19 as therapeutic and as well as immunomodulatory agent from Danieli MG, Piga MA, Paladini A, et al. Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scand J Immunol. 2021 Nov;94(5):e13101. doi: 10.1111/sji.13101.	Thanks for your comment. We added the reference based on your recommendation.
	Page 7, line 93: In your sentence "In addition to immunoglobulin anti-inflammatory activity, IT ?...." Please specify which is IT: IVIG? convalescent plasma? Pentaglobin? If IVIG, the different mechanisms of action are summarized in the updated review cited above.	This part was edited as below "One study which compared neutralizing antibody with IVIg, showed that neutralizing antibody can stop viral replication through blocking the receptor binding, preventing the virus from further damaging the target cell, or preventing uncoating of the virus once inside the cytoplasm."
	Needs some language corrections	Thanks for your comment. The manuscript was reread closely and the errors were corrected.
	In the Summary and in all the text it is written pentaglobin or Pentaglobin, which is (I suppose) more correct	Thanks for your comment. As Pentaglobin is a brand name, we changed it to "IgM-enriched immunoglobulin" in the manuscript.